Links

Homepage

Stock List

Search by Ticker

News

Login

(:CELG)
Stock Analysis

CELG0
0%0

Stock Analysis

The following stock analysis is based on 7.8 years of data (i.e. since Oct 31, 2012). All the stock history has been downloaded.

Stock Exchange

trades on the exchange in dollars.

Sector

It is in the sector.

Current Status of

It is currently trading at $ ($ the previous day).

Financials

The current Canada / US exchange rate is 1.34035.



Will This Trend Continue?

The year over year average increase is -100.0% per year assuming steady exponential growth. The actual 5 year average is -0.06. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year105.1037325581422.4+ Above Average
2 year85.835904977375-15.4- Below Average
3 year101.45745833333-14.5- Below Average
4 year118.726585365858+ Above Average
5 year109.93852830189-0.8- Below Average

Risk

The worst drop it has had in recent years is -59.6%. It has a up and down shape to the stock curve, which means the stock can have significant gains followed by losses. Good for day trading, but needs to be watched if held for any significant amount of time.

Stock shape test

DAYS AG0PRICE
10RISING
30RISING
60108.24DROPPING
150108.24RISING
36593.07RISING
80077.66RISING
1200123.01DROPPING
160099.99RISING
2000118.75DROPPING


Tradingview BuySell Widget

Yahoo News Feed

Bristol Myers Is Launching A New MS Drug — But Is BMY Stock A Buy?

Wed, 22 Jul 2020 12:00:05 Bristol Myers stock has slipped this year. But the addition of Celgene has helped bolster the pharmaceutical companyand's sales. So is BMY stock a buy?... Read Full Article

Stocks - Peloton, PayPal Surge in Premarket on Boost From Lockdowns

Thu, 07 May 2020 08:46:25 By Geoffrey Smith... Read Full Article

Celgene Corporation -- Moody's withdraws Celgene's ratings

Fri, 13 Mar 2020 20:22:11 Moody's Investors Service ("Moody's") withdrew the A3 senior unsecured ratings of Celgene Corporation ("Celgene"). Celgene is a subsidiary of Bristol-Myers Squibb Company ("Bristol"). The majority of Celgene's debt was exchanged into direct obligations of Bristol through an exchange offer.... Read Full Article

GAMCO Investors Exits Viacom, Spark Therapeutics

Fri, 28 Feb 2020 15:33:39 Firmand's largest sales of the 4th quarter Continue reading...... Read Full Article

Ronald Muhlenkampand's Firm Exits Celgene, Trims Gilead Position

Wed, 26 Feb 2020 19:22:32 Investorand's largest sales of the 4th quarter Continue reading...... Read Full Article

Pioneer Investments Cuts Linde, McDonaldand's

Tue, 25 Feb 2020 16:26:49 Firm’s largest sales of the 4th quarter Continue reading...... Read Full Article

Ronald Muhlenkampand's Firm Buys 3 Stocks in 4th Quarter

Fri, 21 Feb 2020 17:13:26 Guru’s firm also gains a position in Bristol-Myers Squibb following its acquisition of Celgene Continue reading...... Read Full Article

David Abrams Buys 2 Stocks in 4th Quarter

Thu, 20 Feb 2020 17:37:50 Guru’s positions in Celgene, Altaba were also eliminated Continue reading...... Read Full Article

David Rolfeand's Firm Cuts Apple, Visa

Wed, 19 Feb 2020 17:09:47 Investorand's largest sales of the 4th quarter. Continue reading...... Read Full Article

Eaton Vance Exits Celgene, Trims Amgen Position

Tue, 04 Feb 2020 19:32:23 Health care-focused fundand's largest sales of the 4th quarter Continue reading...... Read Full Article

Acceleron stock soars on lung drug trial data

Tue, 28 Jan 2020 10:26:18 Just months after its first product was approved by the FDA, Cambridge’s Acceleron Pharma is closer to executing a one-two punch after announcing new clinical trial data this week.... Read Full Article

Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company

Tue, 14 Jan 2020 18:02:10 Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the ...... Read Full Article

NASDAQ: CELG Investor Notice: Update in Lawsuit against Celgene Corporation announced by Shareholders Foundation

Tue, 07 Jan 2020 12:10:00 SAN DIEGO, CA / ACCESSWIRE / January 7, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Celgene Corporation (CELG) shares. Investors, who purchased shares of Celgene Corporation (CELG) in 2016 or earlier and continue to hold any of ...... Read Full Article

An Unusual Investment With 125% Upside

Mon, 30 Dec 2019 15:35:59 Discussion of the Bristol-Myers contingent value right Continue reading...... Read Full Article

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

Mon, 16 Dec 2019 12:30:10 GAITHERSBURG, Md., Dec. 16, 2019 -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune.... Read Full Article

Bristol-Myers business development head Biondi departs

Thu, 12 Dec 2019 18:06:10 Bristol-Myers Squibb Co's head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday. Biondi joined Bristol-Myers in 2002 and had been ...... Read Full Article

Biotech ETFs Hit New Highs on Deal Activities

Tue, 10 Dec 2019 15:10:03 Following the new deals in the healthcare space, a few biotech ETFs hit new highs.... Read Full Article

Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise

Mon, 09 Dec 2019 14:02:00 Bristol-Myers shares edged higher Monday after the group said a new cancer treatment, which it acquired through its $74 billion takeover of Celgene Corp., had solid results from an early clinical trial. Bristol-Myers said a study presented to the American Society ...... Read Full Article

Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

Sat, 07 Dec 2019 19:00:00 Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for ...... Read Full Article
<